Advertisement

Topics

Human Epidermal Growth Factor receptor EGF R - Biotech, Pharma and Life Science Channel

04:31 EDT 20th September 2018 | BioPortfolio

The human epidermal growth factor receptor (HER) family members include EGFR (erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4) that are structurally related, and all except HER3 contain intracellular tyrosine kinase (tk) domain. All of the HER members, except HER2, bind to extracellular ligands

EGFR, a valid target in many epithelial malignancies, is a transmembrane protein with an extracellular ligand binding domain joined to an intracellular tyrosine kinase domain. Activation of EGFR induces a cascade of downstream signaling through several pathways, such as mitogenac tivated protein kinase (MAPK) and PI3-kinase / Akt/mTOR, resulting in cellular proliferation, differentiation, survival, motility, adhesion, and repair. EGFR is overexpressed or abnormally activated in several epithelial malignancies. Several antibodies targeting EGF-R and small molecules inhibiting the EGF-R tyrosine kinase have been approved and are used for treatment of colorectal cancer, squamous cell cancer of the head & neck or pancreatic cancer, respectively. EGF-R targeting therapeutics achieved 2008 sales of US$ 3.35 bln.

The pipeline of novel EGF-R targeting molecules is rather full and includes novel antibody as well as vaccine approaches and small molecules with a broader inhibition profile. At least six next generation antibodies against EGF-R are already in clinical development and more than ten biologics are preclinical R&D including dual target antibodies or vaccines. The small molecule pipeline is focused on dual EGF-R and Her2 as well as pan-Her tk inhibitors, but also includes multi-target EGF-R tk inhibitors.

Source; ReportLinker - Competitor Analysis: EGF-R Agonists and Antagonists

Add the Human Epidermal Growth Factor receptor news channel to your RSS reader;

News Articles [4212 Associated News Articles listed on BioPortfolio]

Numab Appoints Immunotherapy Pioneer Ignacio Melero as Scientific Advisor

Company progresses development of tri-specific IO therapeutic ND021 ND021 is designed to improve the risk-benefit profile over conventional IO combination therapies ...

Enterprise File Synchronization and Sharing EFSS Market by Component Standalone EFSS Solution, Integrated EFSS Solution, Services, Deployment Type Cloud OnPremises, Organization Size, Industry Vertical, and Region Global Forecast to 2023 [Report Update

The emphasis of businesses on the security aspects of the corporate data is driving the growth of the EFSS market. The global Enterprise File Synchronization and Sharing EFSS market size is expected t...

Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the Tools for Human Drug and Brain Research (THuNDR2) Initiative from the Wellcome Trust

Geneva, Switzerland, 20 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has joined ...

Human medicines European public assessment report (EPAR): Fortacin, lidocaine / prilocaine, Revision: 7, Authorised

Human medicines European public assessment report (EPAR): Kymriah, tisagenlecleucel, Revision: 0, Authorised

Human medicines European public assessment report (EPAR): Rasilez HCT, aliskiren / hydrochlorothiazide, Revision: 14, Authorised

Human medicines European public assessment report (EPAR): Ninlaro, ixazomib, Revision: 4, Authorised

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma

– Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus everolimus in the phase 3 pivotal METEOR tria...

Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia

Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of...

Changes in responsibility areas of the Orion Group Executive Management Board

ORION CORPORATION       STOCK EXCHANGE RELEASE      19 SEPTEMBER 2018 at 11.45 a.m. EEST                      Changes in responsibility areas of the Or...

Events [0 Results]

None

Companies [791 Associated Companies listed on BioPortfolio]

Rapamycin Holdings, Inc.

Rapamycin Holdings holds the exclusive licenses for Rapamycin-related research discoveries made at the University of Texas Health Science Center San Antonio. The company is levera...

BioNeutral Group Inc.

BioNeutra is a multiple-award winning, sector-leading, science-based company committed to improving public health. The media describes it as “…a rising star.” Its l...

Blue Ox Healthcare Partners, LLC

Blue Ox Healthcare Partners, LLC is a private equity investment firm focused on providing capital to growth stage healthcare companies targeting the industry’s transformation...

Shore Capital Partners, LLC

Shore Capital is a Chicago-based private equity firm focused exclusively on microcap healthcare investments. Shore supports management partners with capital, business development ...

WellSky

WellSky is a technology company advancing human wellness worldwide. Our software and professional services address the continuum of health and social care — helping businesse...

Twentyeight-Seven Therapeutics

Twentyeight-Seven Therapeutics is a biotechnology company focused on the modulation of non-coding RNA (ncRNA) function to treat cancer and other human diseases. Targeting ncRNA mo...

MarketsandMarkets and SRI International

MarketsandMarkets provides quantified B2B competitive intelligence research on high-growth emerging niche markets that will impact future revenue mix of 70-80 percent of companies...

Linde plc

In the 2016 financial year, The Linde Group generated revenue of EUR 17 billion, making it one of the leading gases and engineering companies in the world, with approximately 60,0...

StemExpress

StemExpress is a leading Biospecimen Provider of human bone marrow, cord blood, peripheral blood, mobilized peripheral blood, maternal blood, diseased blood, and human ...

UF Innovate | Sid Martin Biotech

UF Innovate | Sid Martin Biotech is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. Sid Martin has been honore...

Clinical Trials [9176 Associated Clinical Trials listed on BioPortfolio]

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection

A Clinical Study of PD-L1 Antibody ZKAB001 in Limited Stage of High-grade Osteosarcoma

This is a Phase 1+2, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody tar...

A Clinical Study of PD-L1 Antibody ZKAB001 in Recurrent or Metastatic Cervical Cancer

This is a Phase 1, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targe...

A Clinical Study of PD-L1 Antibody ZKAB001 in Locally Advanced and Metastatic Urothelial Carcinoma

This is a Phase 1+2, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody tar...

MORDOR II Burkina Faso: Longitudinal Trail

Globally, childhood mortality has shown a promising downward trend in recent years, however, many sub-Saharan countries still have relatively high child mortality rates. In previous studie...

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

This phase II trial studies how effective talazoparib and temozolomide are for treating participants with extensive-stage small cell lung cancer that has come back after an initial chemoth...

Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy

The aim of the study is to examine the suitability, the so-called validation, of a questionnaire, with which one can grasp the reasons why injections of growth hormones are omitted by pati...

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibod...

Impedancemetry in Patients Monitored for Pulmonary Hypertension

Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for Pulmonary Hypertension

The Tolerability,Safety,PK/PD Study of rhTPO in the Patients With Liver Function Impairment

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics and pharmacodynamics of recombinant human thrombopoietin in the patients with different degree of liver ...

PubMed Articles [26063 Associated PubMed Articles listed on BioPortfolio]

Autochthonous Human Case of Seoul Virus Infection, the Netherlands.

Orthohantaviruses are a group of rodentborne viruses with a worldwide distribution. The orthohantavirus Seoul virus (SEOV) can cause hemorrhagic fever with renal syndrome in humans and is distributed ...

Singular stochastic control model for algae growth management in dam downstream.

A stochastic control model for finding an ecologically sound, fit-for-purpose dam operation policy to suppress bloom of attached algae in its downstream is presented. A singular exactly solvable and a...

Proanthocyanidins: novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells.

Psoriasis is a common, chronic, inflammatory skin disease that affects 2%-4% of the global population. Recent studies have shown that increased oxidative stress (OS) and T-cell abnormalities are centr...

Parents' concerns regarding the growth characteristics of their adolescents: a qualitative inquiry in Iran.

In recent times, parents have become increasingly concerned, both subjectively and objectively, about their adolescents' body height/weight growth. Parent-adolescent interactions about this issue and ...

Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma.

Chemical entities with structural diversity were introduced as candidates targeting adenosine receptor with different clinical activities, containing 3,7-dihydro-1H-purine-2,6-dione, especially adenos...

Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation.

Pentabromopseudilin (PBrP) is a marine antibiotic isolated from the marine bacteria Pseudomonas bromoutilis and Alteromonas luteoviolaceus. PBrP exhibits antimicrobial, anti-tumour, and phytotoxic act...

Newer human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents.

Human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2), being an age-old target, has attracted attention recently for anticancer drug development. Mycophenolic acid (MPA), a well-known immunosuppres...

Modulation of cytokine/chemokine production in human macrophages by bisphenol A: A comparison to analogues and interactions with genistein.

The immunotoxicant bisphenol A (BPA) may produce toxic effects on organs and systems, in part, by altering the secretion of cytokines and chemokines. However, systematic studies of the effects of BPA,...

Inhibition of α-, β-, γ-, and δ-carbonic anhydrases from bacteria and diatoms with N'-aryl-N-hydroxy-ureas.

The inhibition of α-, β-, γ-, and δ-class carbonic anhydrases (CAs, EC 4.2.1.1) from bacteria (Vibrio cholerae and Porphyromonas gingivalis) and diatoms (Thalassiosira weissflogii) with a panel of...

Synthesis and pharmacological evaluation of novel isoquinoline N-sulphonylhydrazones designed as ROCK inhibitors.

In this study, we synthesized a new congener series of N-sulphonylhydrazones designed as candidate ROCK inhibitors using the molecular hybridization of the clinically approved drug fasudil (1) and the...

Videos

None available.

Medical and Biotech [MESH] Definitions

A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF related peptides including TRANSFORMING GROWTH FACTOR ALPHA, amphiregulin, and heparin-binding EGF-like growth factor. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.

A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. EPIDERMAL GROWTH FACTOR exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and epithelial cells.

A fibroblast growth factor that preferentially activates FIBROBLAST GROWTH FACTOR RECEPTOR 4. It was initially identified as an androgen-induced growth factor and plays a role in regulating growth of human BREAST NEOPLASMS and PROSTATIC NEOPLASMS.

A fibroblast growth factor receptor that is found in two isoforms. One receptor isoform is found in the MESENCHYME and is activated by FIBROBLAST GROWTH FACTOR 2. A second isoform of fibroblast growth factor receptor 2 is found mainly in EPITHELIAL CELLS and is activated by FIBROBLAST GROWTH FACTOR 7 and FIBROBLAST GROWTH FACTOR 10. Mutation of the gene for fibroblast growth factor receptor 2 can result in APERT SYNDROME.

A cell surface protein-tyrosine kinase receptor that is specific for NEUREGULINS. It has extensive homology to and can heterodimerize with the EGF Receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR) and the erbB-2 receptor (RECEPTOR, ERBB-2). Overexpression of the erbB-3 receptor is associated with tumorigenesis.

Advertisement
Quick Search
Advertisement
Advertisement

 
review and buy Human Epidermal Growth Factor receptor EGF R market research data and corporate reports here

Channels Quicklinks